europeanunion

  • An RSV Vaccine From Moderna Passes Phase III Trial Amid Viral Surge

    An RSV Vaccine From Moderna Passes Phase III Trial Amid Viral Surge

    We’re getting ever closer to besting a frequent microscopic source of misery: the respiratory syncytial virus. Late Tuesday, Moderna announced the seemingly successful Phase III trial results of its experimental RSV vaccine. In older adults, the vaccine appeared to be over 80% effective at preventing two or more symptoms linked to lower respiratory infections caused…